Modified messenger RNA (mRNA) for expressing clinically beneficial proteins is an emerging new therapeutic approach that enables the body to produce therapeutic protein, opening up new treatment options for a wide range of diseases.


Recent advances strongly suggest that mRNA rather than recombinant DNA and proteins may be the basis for a new class of drugs.


Messenger RNA can be engineered to transiently express proteins by structurally resembling natural mRNA.

Advances in addressing the inherent challenges of this drug class, particularly related to controlling the stability, translational efficiency and immunogenicity of the mRNA, provide the basis for a broad range of potential applications.

MessengerRNA-based cancer immunotherapies and infectious disease vaccines are currently in clinical development stages.